Could a daily probiotic shield babies from allergies?

NCT ID NCT07490587

Recruiting now Prevention Sponsor: Min-Tze LIONG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a daily probiotic supplement (Bifidobacterium lactis XLTG11) can lower the chance of allergies in healthy infants under 3 years old who are at higher risk. Over 180 days, researchers will track allergy symptoms and analyze gut bacteria changes. The goal is to see if this simple intervention can support immune development and reduce allergic reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bifidobacterium animalis subsp. lactis XLTG11 probiotic
What this could lead to: If it works, this could point toward a simple daily supplement to help prevent allergies in infants at high risk.
What could go wrong: This is an early phase 2 trial, so results are not yet proven. The probiotic may not reduce allergies, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY CHILDREN

Contacts and locations

Locations

Shanghai Sixth People's Hospital
RECRUITING

Pudong, Shanghai Municipality, 201306, China
Universiti Sains Malaysia
NOT_YET_RECRUITING

Pulau Pinang, Pulau Pinang, 11800, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.